Cheapest Way to Get Tirzepatide Legally: 2026 Prices

The cheapest legal way to get tirzepatide in 2026 depends almost entirely on your insurance situation. If you have a commercial plan that covers the drug, Lilly’s savings programs bring the cost to $25 for up to a 3-month prescription of the Zepbound single-dose pen ^[1][6] or as little as $25 for a 1-, 2-, or 3-month prescription of the Mounjaro single-dose pen ^[3]. If you’re on Medicare, the new Medicare GLP-1 Bridge program starts July 1, 2026 and charges a flat $50 per month for the Zepbound KwikPen, regardless of income ^[4]. If you’re on Medicaid in one of the 13 states covering GLP-1s for obesity as of January 2026, copays are typically little or nothing ^[5]. And if you’re paying cash, the cheapest documented route is the Zepbound KwikPen or single-dose vial through LillyDirect self-pay pricing: $299 per month at 2.5 mg, $399 at 5 mg, and $449 at 7.5–15 mg ^[2][6][7]. The $449 price holds only if each refill is purchased within 45 days — miss that window at 7.5–15 mg and regular prices of $499 to $699 apply, while the $299 and $399 prices at the lower doses don’t change ^[2]. Pen needles or syringes are sold separately ^[2][6].

Here’s how the main routes compare:

Route	Who qualifies	What you pay
Zepbound Savings Program (single-dose pen)	Commercially insured with Zepbound coverage	Starting at $25 for up to a 3-month prescription [1][6]
Mounjaro Savings Card (single-dose pen)	Commercially insured with Mounjaro coverage	As little as $25 for a 1-, 2-, or 3-month prescription [3]
Medicare GLP-1 Bridge (KwikPen only)	Eligible Medicare Part D patients	$50 per month starting July 1, 2026 [4]
Medicaid (covering states)	Enrollees in the 13 covering states, subject to controls	Little or no copay [5]
Zepbound self-pay (KwikPen or vial)	Cash-paying patients 18 or older residing in the US or Puerto Rico, with an on-label prescription, who agree not to seek third-party reimbursement [2]	$299–$449 per month, plus needles [2][6]
Mounjaro non-covered tier (single-dose pen)	Commercially insured without Mounjaro coverage	As low as $499 for a 1-month fill [3]

One thing to understand before comparing any of these numbers: tirzepatide comes in three different Zepbound presentations that are priced differently — a single-dose pen, a single-dose vial, and a single-patient-use KwikPen ^[2][6]. Prices are not interchangeable across them. The $25 card price applies to the single-dose pen, the $299–$449 self-pay prices apply to the KwikPen and vial, and the Medicare Bridge covers only the KwikPen ^[4]. Mixing up the device is one of the most common ways people overpay.

What is tirzepatide, and why does the device change the price?

Tirzepatide is the active ingredient in Zepbound, made by Lilly ^[7]. Zepbound is a dual GIP/GLP-1 receptor agonist approved for adults with obesity, or adults with overweight plus at least one weight-related medical problem, and also for adults with moderate-to-severe obstructive sleep apnea (OSA) and obesity ^[7][8]. It is not for cosmetic weight loss ^[7].

Zepbound comes in six doses: 2.5, 5, 7.5, 10, 12.5, and 15 mg. The 2.5 mg dose is a starting dose only and is not an approved maintenance dose ^[7][8]. The recommended maintenance doses are 5, 10, or 15 mg once weekly for weight reduction, and 10 or 15 mg for OSA ^[7][8].

The same medicine is sold in three physical forms, and the price paid depends on which one is dispensed ^[2][6]:

• Single-dose pen — the insurance product. Each pen holds one dose and the needle is included ^[6].
• Single-dose vial — a self-pay product sold exclusively through LillyDirect; needles and syringes are bought separately ^[6].
• KwikPen for single-patient use — a multi-dose pen that delivers a full month (four doses) in one device; pen needles are bought separately ^[6][7].

Mounjaro is also tirzepatide in a single-dose pen, with its own separate savings card program ^[3].

What’s the cheapest route if my commercial insurance covers the drug?

If you’re commercially insured and your plan covers Zepbound, the Zepbound Savings Program brings the single-dose pen down to a starting price of $25 for up to a 3-month prescription ^[1][6]. A month is defined as 28 days and up to 4 single-dose pens, and savings are subject to monthly and annual limits set by Lilly ^[2]. The program is not insurance, and Lilly can terminate, rescind, revoke, or amend the card eligibility and terms at any time without notice ^[2].

For Mounjaro, the Mounjaro Savings Card gets the single-dose pen for as little as $25 for a 1-, 2-, or 3-month prescription if you’re commercially insured with Mounjaro coverage ^[3]. The documented caps: up to $150 maximum savings per 1-month fill, $300 per 2-month fill, $450 per 3-month fill, and up to $1,950 maximum savings per calendar year, with a maximum of 13 fills per calendar year ^[3]. The card expires and savings end on December 31, 2026 ^[3].

Both cards exclude anyone enrolled in a state, federal, or government-funded healthcare program — including Medicaid, Medicare, Medicare Part D, Medicare Advantage, Medigap, DoD, VA, TRICARE/CHAMPUS, and state prescription drug assistance programs ^[2][3]. Other conditions for the Mounjaro card include having commercial drug insurance, being a US or Puerto Rico resident, being 18 or older, having an on-label prescription, providing a valid HIPAA authorization, and activating the card ^[3].

A few more restrictions on the Mounjaro card worth knowing: members of alternate funding programs (AFPs) are prohibited from using it; savings cannot be combined with other coupons or discount cards; and reimbursement may not be sought from an HSA or FSA for the savings amount ^[3]. Lilly also warns that card savings may be reduced or eliminated if your plan imposes requirements, only partially covers the drug, removes coverage, or does not apply card payments toward your copay, deductible, or coinsurance ^[3].

On the coverage side, Lilly’s provider page notes that commercial CVS Caremark coverage for Zepbound expands October 1, with some employers reinstating earlier ^[2].

How does the Medicare GLP-1 Bridge get tirzepatide for $50 a month?

Starting July 1, 2026, Medicare’s GLP-1 Bridge program covers certain GLP-1 weight-loss medicines at a flat $50 per month, no matter your income ^[4]. For tirzepatide, that means the Zepbound KwikPen only — the single-dose Zepbound pen and Zepbound vials are not covered under this program ^[4]. The program also covers Foundayo (tablet) and Wegovy (injection or tablet) ^[4].

The $50 does not count toward your Medicare Part D deductible or your yearly out-of-pocket limit, and drugs bought through the program are not eligible for the Medicare Prescription Payment Plan ^[4]. Lilly also notes that injection supplies and pen needles are sold separately, and the program is not a guarantee of coverage ^[1][2].

Eligibility requires all four of these ^[4]:

1. Medicare Part D drug coverage, either through a standalone drug plan or a Medicare health plan that includes drug coverage. Certain plan types are excluded, including private fee-for-service plans, cost contract plans, and PACE organizations.
2. No access to a GLP-1 through your own Medicare drug plan. GLP-1 drugs are defined as products containing semaglutide, tirzepatide, orforglipron, dulaglutide, or liraglutide. If you’ve been getting a GLP-1 through your plan, you keep getting it that way.
3. No type 2 diabetes, moderate-to-severe sleep apnea, or fatty liver disease. If you have any of these, your Medicare drug plan may already cover a GLP-1 for you.
4. Age 18 or older plus a BMI threshold: BMI of 35 or higher; or BMI of 30 or higher with certain types of heart failure, hard-to-control high blood pressure, or chronic kidney disease (stage 3a or above); or BMI of 27 or higher with prediabetes, or a prior heart attack, stroke, or blocked arteries in your legs or arms.

The process works like this: your doctor sends a prescription to the pharmacy; the pharmacy may ask for your Medicare ID number (or look it up with the last four digits of your Social Security Number); your doctor submits a form to get Medicare’s approval; and Medicare sends you a letter confirming coverage. You pick up the medicine and pay $50 for a one-month supply ^[4]. Refills don’t need new Medicare approval as long as you stay on the same drug, even if your dose changes ^[4].

For questions, call 1-800-MEDICARE (1-800-633-4227), or TTY 1-877-486-2048 ^[4].

Does Medicaid cover tirzepatide for weight loss?

It depends on your state. Medicaid enrollees already pay little or no copays for prescription drugs, so when tirzepatide is covered, it’s close to free ^[5]. Under the Medicaid Drug Rebate Program, states must cover nearly all FDA-approved drugs from participating manufacturers for medically accepted indications — but weight-loss drugs are a statutory exception, so obesity coverage is optional for states ^[5].

Coverage is required for other indications: diabetes, cardiovascular disease (Wegovy, since March 2024), and moderate-to-severe OSA in adults with obesity (Zepbound, since December 2024) ^[5]. For children, coverage is required when medically necessary under the EPSDT benefit ^[5].

As of January 2026, 13 state Medicaid programs covered GLP-1s for obesity under fee-for-service ^[5]. KFF’s 2025 budget survey found 16 states covering as of October 2025, but since then California, New Hampshire, Pennsylvania, and South Carolina dropped obesity coverage; North Carolina ended coverage in October 2025 over a budget stalemate and reinstated it in December 2025 ^[5]. When states do cover these drugs, they typically apply utilization controls such as prior authorization ^[5].

Two federal developments may change this picture. In November 2025, the administration announced a deal with Eli Lilly and Novo Nordisk on GLP-1 prices for Medicare, Medicaid, and direct purchase through TrumpRx ^[5]. And in December 2025, CMS announced the BALANCE model, a five-year voluntary CMMI model for state Medicaid programs, Part D plans, and manufacturers, with state and manufacturer intent to participate due January 8, 2026, an expected start in May 2026, and Part D implementation in January 2027 ^[5]. Medicare coverage of GLP-1s for obesity treatment itself remains prohibited under current law ^[5].

What does Zepbound cost per month without insurance?

The published self-pay prices apply to the Zepbound KwikPen and the single-dose vial, which are priced identically ^[2][7]. A 1-month supply is defined as 28 days — either 4 single-dose vials or 1 KwikPen (4 doses per KwikPen) ^[2][6]. The purchase offer is applied automatically starting February 23, 2026 ^[2][7], and self-pay savings are auto-applied through LillyDirect ^[6].

Dose	Self-pay price per month	Regular price if the 45-day refill window is missed
2.5 mg	$299 [2][6][7]	$299 [2]
5 mg	$399 [2][6]	$399 [2]
7.5 mg	$449 [2][6]	$499 [2][6]
10 mg	$449 [2][6]	$699 [2][6]
12.5 mg	$449 [2][6]	$699 [2][6]
15 mg	$449 [2][6]	$699 [2][6]

The $449 price at 7.5–15 mg reflects the Zepbound Self Pay Journey Program purchase offer ^[2][6]. No prior authorization is needed for self-pay, but the program requires patients to certify that they’ve been prescribed the vial or KwikPen for an approved use consistent with FDA labeling ^[2]. Taxes and fees may apply on top of these prices ^[2][6].

The KwikPen self-pay card also has documented maximum monthly savings caps: up to $215 at 2.5 mg, $115 at 5 mg, $65 at 7.5 mg, and $271 at 10, 12.5, or 15 mg ^[2].

What happens to the price if a refill is late?

This is the trap in the self-pay program. To keep the $449 price at 7.5, 10, 12.5, or 15 mg, the program requires each refill purchase to be completed within 45 days of the delivery or receipt date of the previous vial or KwikPen fill ^[2][6]. Past 45 days, the purchase offer no longer applies and regular prices kick in: $499 for 7.5 mg and $699 each for 10, 12.5, and 15 mg ^[2][6]. The lower doses are unaffected — regular prices at 2.5 mg ($299) and 5 mg ($399) are the same as the offer prices ^[2].

The offer is valid only for the 7.5–15 mg doses of the vial or KwikPen, and both new and existing patients are eligible ^[2]. Lilly may terminate, rescind, revoke, or amend the offer at any time without notice, for any reason ^[2].

Where can a self-pay Zepbound prescription be filled, and what costs extra?

The single-dose vial is exclusively available through LillyDirect, self-pay only, with free delivery and pickup available ^[6]. The vial requires a separate needle and syringe purchase ^[6]. The KwikPen requires a separate pen needle purchase ^[6].

The KwikPen accepts select insurance and self-pay, with free delivery and pickup available ^[6]. Since March 16, 2026, KwikPen self-pay pricing has been available at LillyDirect and major pharmacies nationwide, starting at $299 for the 2.5 mg dose ^[8]. The KwikPen Self-Pay Savings Card at zepbound.lilly.com/savings is open to all patients, including those without insurance coverage, and gets the same self-pay prices offered through LillyDirect ^[8]. That card applies only to the KwikPen — not to single-dose vials and not to the single-dose pen ^[8].

The single-dose pen accepts insurance and comes with free delivery, and the needle is included in each pen ^[6]. Zepbound purchases are HSA/FSA eligible, though eligibility may vary by plan ^[1][6]. LillyDirect prescribing is open to all US-licensed prescribers and is listed as a pharmacy option in all major electronic health record systems ^[7].

What fine print comes with the self-pay savings card?

The Zepbound KwikPen self-pay card is for cash-paying patients only ^[2]. By using it, patients agree not to seek or accept reimbursement for their out-of-pocket costs from any third-party payer — including private insurance or state or federal healthcare programs — and not to apply those costs toward any deductible or true out-of-pocket requirement ^[2]. Eligibility requires US or Puerto Rico residency and age 18 or older ^[2]. The program is not insurance, and Lilly can terminate or amend its terms at any time ^[2][6].

What if my commercial plan doesn’t cover the drug at all?

If you’re commercially insured but your plan doesn’t cover Mounjaro, the Mounjaro card’s non-covered tier gets the single-dose pen for as low as $499 for a 1-month fill ^[3]. That tier’s caps: up to $647 maximum monthly savings, up to $8,411 maximum annual savings, and up to 13 fills per calendar year ^[3].

For Zepbound, Lilly directs commercially insured patients with no Zepbound coverage to the KwikPen at a starting price of $299 per month ^[1]. Note that the $299 self-pay price is for the KwikPen or vial — not the Zepbound single-dose pen ^[1].

How do I check my coverage before the prescription is written?

Zepbound has an insurance-check tool at zepbound.lilly.com/insurance-check, and providers can use the Electronic Benefits Tool ^[1][2]. The tool’s results are based on details you provide and are not a guarantee of coverage — Lilly says patients should contact their insurer directly to confirm ^[2]. Coverage can differ if you have Medicaid, VA, DoD, TRICARE, or another state or federal benefit program ^[1].

For Mounjaro, card eligibility is checked through attestation questions at enrollment.mounjaro.lilly.com; if you’re not eligible, pricinginfo.lilly.com/mounjaro lists other affordability options ^[3]. If you have a Medicare drug plan or a Medicare Advantage plan with drug coverage, the Medicare Prescription Payment Plan (M3P) is a free budgeting tool that spreads drug costs across fixed monthly payments over the plan year, and you can opt in at any time ^[3].

Which device and dose choices affect what I pay?

The single-dose pen is the insurance and $25-card product; the vial and KwikPen are the self-pay products ^[1][2][6][8]. The Medicare GLP-1 Bridge covers the KwikPen only ^[4]. So the device tied to your cheapest route depends on which route you qualify for — that’s a coverage question, not a clinical one, and dose decisions belong to your prescriber.

Two safety points that also affect cost choices: the label says a KwikPen should not be shared with other people, even with a new needle, because of infection risk ^[7]. And Zepbound should not be used together with other tirzepatide-containing products or any GLP-1 receptor agonist ^[7][8].

Is the price worth it? What the studies show

In the 72-week SURMOUNT-1 trial in adults without diabetes, average weight loss was 15.0% (34 lbs) at 5 mg, 19.5% (44 lbs) at 10 mg, and 20.9% (48 lbs) at 15 mg, versus 3.1% (7 lbs) for placebo ^[7].

In SURMOUNT-5, a 72-week open-label study comparing Zepbound against injectable Wegovy, participants on Zepbound at their maximum tolerated dose lost an average of 20.2% (50 lbs), versus 13.7% (33 lbs) for Wegovy at its maximum tolerated dose ^[7]. Because the study was open-label, the findings are less certain than a blinded trial’s would be ^[7].

According to Lilly’s February 2026 announcement, Zepbound was the most prescribed weight management medication in 2025, and 1 in 3 new patients starting a branded weight management medication that year was prescribed Zepbound self-pay vials ^[7]. The same announcement states that LillyDirect self-pay pricing is a 50% or greater discount compared with the list price of other GLP-1 obesity medicines, and that over 1 million patients accessed Lilly treatments through LillyDirect in 2025 ^[7].

What safety warnings come with tirzepatide?

Zepbound carries a boxed warning that it may cause thyroid tumors, including thyroid cancer. Watch for a lump or swelling in your neck, hoarseness, trouble swallowing, or shortness of breath, and tell your healthcare provider if you have any of these symptoms ^[7].

The label says Zepbound should not be used if you or any family member has ever had medullary thyroid carcinoma (MTC), if you have Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), or if you’ve had a serious allergic reaction to tirzepatide or any of its ingredients ^[7].

Serious possible side effects include severe stomach problems, dehydration leading to kidney problems, gallbladder problems, pancreatitis, serious allergic reactions, and low blood sugar ^[7].

This page describes published prices and program rules only — it isn’t medical advice. Talk to your healthcare provider about whether tirzepatide is right for you, and about which dose and device fit your situation.

Sources

1. Eli Lilly and Company. Savings & Insurance Options | Zepbound (tirzepatide).
2. Eli Lilly and Company. Coverage, Affordability, and Savings | Zepbound (tirzepatide).
3. Eli Lilly and Company. Savings & Coverage | Mounjaro (tirzepatide).
4. Medicare. Medicare GLP-1 Bridge: GLP-1 Drugs for $50 a Month. July 1, 2026.
5. KFF. Medicaid Coverage of and Spending on GLP-1s. January 16, 2026.
6. Eli Lilly and Company. Authentic Zepbound (tirzepatide) Shipped to You | LillyDirect.
7. Eli Lilly and Company. Zepbound (tirzepatide), the most prescribed weight management medication in 2025, now available in multi-dose KwikPen. February 23, 2026.
8. Eli Lilly and Company. Media Statement: Zepbound (tirzepatide) KwikPen now available at self-pay pricing at major pharmacies nationwide in addition to LillyDirect. March 16, 2026.
9. Business Wire. Amazon Pharmacy Expands Access to Eli Lilly’s Zepbound KwikPen for Weight Management. March 9, 2026.
10. Eli Lilly and Company. Coverage, Affordability, and Savings | Zepbound (tirzepatide).
11. Eli Lilly and Company (LillyDirect). Authentic Mounjaro (tirzepatide) Shipped to You | LillyDirect.
12. TrumpRx. Mounjaro on TrumpRx.
13. US Food and Drug Administration. FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize.
14. GoodRx. Zepbound 2026 Prices, Coupons & Savings Tips.
15. SingleCare. Zepbound Coupons 2026: Up to 80% Discount - How Much Does Zepbound Cost?
16. TrumpRx. Zepbound Vial on TrumpRx.
17. Lilly Cares. How to Apply.
18. US Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations.